Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
4D Molecular Therapeutics Inc
(NQ:
FDMT
)
16.16
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1
Open
16.16
Bid (Size)
15.50 (3)
Ask (Size)
16.95 (3)
Prev. Close
16.16
Today's Range
16.16 - 16.16
52wk Range
9.440 - 36.25
Shares Outstanding
42,052,980
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
September 12, 2024
From
The Schall Law Firm
Via
Business Wire
Performance
YTD
-23.95%
-23.95%
1 Month
+9.86%
+9.86%
3 Month
-29.06%
-29.06%
6 Month
-49.53%
-49.53%
1 Year
+4.19%
+4.19%
More News
Read More
The Latest Analyst Ratings For 4D Molecular Therapeutics
September 09, 2024
Via
Benzinga
4DMT Announces Presentations at Upcoming Retina Conferences
September 05, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
July 18, 2024
Via
Benzinga
Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
June 26, 2024
Via
Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
June 07, 2024
Via
Benzinga
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
September 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
August 27, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 12, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024
August 09, 2024
Via
InvestorPlace
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
August 08, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
August 05, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 18, 2024
Via
Benzinga
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
July 17, 2024
From
The Schall Law Firm
Via
Business Wire
4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
July 17, 2024
Via
Benzinga
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
July 17, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 17, 2024
Via
Benzinga
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
June 24, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
June 18, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
June 08, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Via
Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.